Sun Pharma Advanced Research Co. Ltd.

As of June 30, 2026, Sun Pharma Advanced Research Co. Ltd. carries a market capitalization of 76.18B, placing it among publicly traded companies globally. Its enterprise value stands at 76.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Sun Pharma Advanced Research Co. Ltd. has 324.52M shares outstanding.

As of June 30, 2026, Sun Pharma Advanced Research Co. Ltd. trades at a trailing price-to-earnings ratio of 4.81.

As of June 30, 2026, Sun Pharma Advanced Research Co. Ltd. trades at an EV/EBITDA multiple of 4.75 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.99 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.78 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 76.18B versus a market cap of 76.18B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 39.05M in revenue per employee across its workforce of 489.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Sun Pharma Advanced Research Co. Ltd. recorded an income tax benefit of -1.40M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 15.84B, leaving 15.84B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Sun Pharma Advanced Research Co. Ltd.'s stock has gained approximately 31.33% over the past 52 weeks. The 50-day moving average sits at 195.83, while the 200-day moving average is 176.35.

Over the twelve months ended June 30, 2026, Sun Pharma Advanced Research Co. Ltd. generated 19.09B in revenue and converted that into 15.84B in net income, yielding earnings per share of 48.84. EBITDA reached 16.04B, while operating income came in at 16.07B.

Over the twelve months ended June 30, 2026, Sun Pharma Advanced Research Co. Ltd. posted a gross margin of 97.04, reflecting its pricing power and cost economics. The operating margin of 84.17 and net profit margin of 82.97 provide insight into operational efficiency.

Sun Pharma Advanced Research Co. Ltd.'s most recent stock split took place on March 16, 2016 with a 146:147 split ratio.